Abstract
Cardiovascular disease is the first cause of morbidity and mortality in dialysis patients. Hyperphosphatemia and elevated serum calcium-phosphate levels have recently been investigated as inducing factors on extraskeletal calcification in this population. In vitro studies demonstrated that human aortic smooth muscle cells calcify when incubated in a high phosphate medium, where calcium and calcitriol are not changed. Furthermore, the lack of inhibitory proteins, such as fetuin and matrix Gla protein, is a possible main determinant of calcium-phosphate deposition in soft tissues. The classical treatment of hyperphosphatemia and secondary hyperparathyroidism in dialysis patients consists of calcium-based phosphate binders and calcitriol administration. Unfortunately, this "first-generation" therapy is not free of dramatic side effects. New free-calcium and -aluminum phosphate binders, new vitamin D metabolites, and calcimimetics are examples of "second-generation" therapies that may prevent vascular calcification and possibly prevent some of the burden of cardiovascular disease in uremia.
| Original language | Italian |
|---|---|
| Pages (from-to) | 25-28 |
| Number of pages | 4 |
| Journal | Italian Heart Journal Supplement |
| Volume | 6 |
| Issue number | 1 |
| Publication status | Published - Jan 2005 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Calcificazioni cardiovascolari e aterosclerosi accelerata in corso di uremia. / Cozzolino, Mario; Butti, Alessandra; Chiarelli, Giusy; Rocca-Rey, Lisa; Santagostino, Gaia; Gallieni, Maurizio; Brancaccio, Diego.
In: Italian Heart Journal Supplement, Vol. 6, No. 1, 01.2005, p. 25-28.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Calcificazioni cardiovascolari e aterosclerosi accelerata in corso di uremia
AU - Cozzolino, Mario
AU - Butti, Alessandra
AU - Chiarelli, Giusy
AU - Rocca-Rey, Lisa
AU - Santagostino, Gaia
AU - Gallieni, Maurizio
AU - Brancaccio, Diego
PY - 2005/1
Y1 - 2005/1
N2 - Cardiovascular disease is the first cause of morbidity and mortality in dialysis patients. Hyperphosphatemia and elevated serum calcium-phosphate levels have recently been investigated as inducing factors on extraskeletal calcification in this population. In vitro studies demonstrated that human aortic smooth muscle cells calcify when incubated in a high phosphate medium, where calcium and calcitriol are not changed. Furthermore, the lack of inhibitory proteins, such as fetuin and matrix Gla protein, is a possible main determinant of calcium-phosphate deposition in soft tissues. The classical treatment of hyperphosphatemia and secondary hyperparathyroidism in dialysis patients consists of calcium-based phosphate binders and calcitriol administration. Unfortunately, this "first-generation" therapy is not free of dramatic side effects. New free-calcium and -aluminum phosphate binders, new vitamin D metabolites, and calcimimetics are examples of "second-generation" therapies that may prevent vascular calcification and possibly prevent some of the burden of cardiovascular disease in uremia.
AB - Cardiovascular disease is the first cause of morbidity and mortality in dialysis patients. Hyperphosphatemia and elevated serum calcium-phosphate levels have recently been investigated as inducing factors on extraskeletal calcification in this population. In vitro studies demonstrated that human aortic smooth muscle cells calcify when incubated in a high phosphate medium, where calcium and calcitriol are not changed. Furthermore, the lack of inhibitory proteins, such as fetuin and matrix Gla protein, is a possible main determinant of calcium-phosphate deposition in soft tissues. The classical treatment of hyperphosphatemia and secondary hyperparathyroidism in dialysis patients consists of calcium-based phosphate binders and calcitriol administration. Unfortunately, this "first-generation" therapy is not free of dramatic side effects. New free-calcium and -aluminum phosphate binders, new vitamin D metabolites, and calcimimetics are examples of "second-generation" therapies that may prevent vascular calcification and possibly prevent some of the burden of cardiovascular disease in uremia.
KW - Calcification
KW - Calcium
KW - Kidney
KW - Phosphates
UR - http://www.scopus.com/inward/record.url?scp=15944386326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=15944386326&partnerID=8YFLogxK
M3 - Articolo
VL - 6
SP - 25
EP - 28
JO - Italian Heart Journal Supplement
JF - Italian Heart Journal Supplement
SN - 1129-4728
IS - 1
ER -